Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
12 Mai 2023 - 1:00PM
Business Wire
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced that Elisabet de los Pinos, PhD, Chief Executive Officer,
will participate in a fireside chat at the JMP Securities Life
Sciences Conference on Tuesday, May 16, 2023, at 2:00 p.m. ET.
The fireside chat will be webcast live and can be accessed from
the “Investors & Media” page under the “Events &
Presentations” section of the Company’s website:
https://ir.aurabiosciences.com/events-and-presentations. A replay
of the webcast will be archived for 90 days following the
presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing virus-like drug conjugates (VDCs), a novel class of
therapies, for the treatment of multiple oncology indications.
Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar;
AU-011), consists of a virus-like particle conjugated with an
anti-cancer agent. Bel-sar is designed to selectively target and
destroy cancer cells and activate the immune system with the
potential to create long-lasting, anti-tumor immunity. Bel-sar is
currently in development for ocular cancers, and Aura has initiated
activities for the global Phase 3 trial evaluating first-line
treatment of early-stage choroidal melanoma, a vision- and
life-threatening form of eye cancer where standard of care with
radiotherapy leaves patients with severe comorbidities, including
major vision loss. Aura plans to pursue development of bel-sar
across its ocular oncology franchise including for the treatment of
patients with choroidal metastasis. In addition, leveraging Aura’s
technology platform, Aura is developing bel-sar more broadly across
multiple cancers, including in patients with non-muscle invasive
bladder cancer. Aura is headquartered in Boston, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230512005009/en/
Investors and Media:
Alex Dasalla Head of Investor Relations and Corporate
Communications adasalla@aurabiosciences.com
Aura Biosciences (NASDAQ:AURA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Aura Biosciences (NASDAQ:AURA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024